RATIONALE AND DESIGN OF THE NL-ENIGMA STUDY, A DUTCH 24-WEEK RANDOMISED CONTROLLED STUDY TO EXPLORE THE EFFECT OF A NUTRITIONAL INTERVENTION ON BRAIN GLUCOSE METABOLISM IN EARLY ALZHEIMER'S DISEASE

Prodromal AD subjects demonstrated greater brain atrophy at 1 year compared with biomarker-negative observational cohort subjects. Avagacestat-treated subjects exhibited greater volume loss than did placebo subjects, a seemingly paradoxical result similar to findings previously reported with other amyloid-lowering treatments such as AN1792 (Fox et al, Neurology 2005) or bapineuzumab (pooled analysis, Fox et al, CTAD 2012).